Hengrui Medicine's fluozoparib gets NMPA acceptance, Q3 profit up 24.5%

Jiangsu Hengrui Medicine announced the National Medical Products Administration's acceptance of its marketing application for fluozoparib capsules. The drug is proposed for first-line treatment of metastatic castration-resistant prostate cancer with DNA repair gene defects, following positive Phase III clinical trial results from July 2025. Fluozoparib has already secured approval for multiple indications, including ovarian and breast cancer, with cumulative R&D investment for related projects reaching approximately CNY 1.11 bn.

The company's third-quarter 2025 report reveals robust financial performance, with total operating income for the first three quarters reaching CNY 23.19 bn, a 14.85% increase year-on-year. Net profit attributable to shareholders rose by 24.50% to CNY 5.75 bn. Operating cash flow for the period significantly increased by 98.68% to CNY 9.11 bn, driven by higher pharmaceutical sales and upfront payments from overseas licensing.

Shareholders are invited to a performance briefing on November 4, 2025, to discuss the third-quarter results. The briefing will be held online via the Shanghai Stock Exchange Roadshow Center.